戻る Agenda
[V7-S3] Various Initiatives after Marketing of Regenerative Medical Products
Session Chair(s)
Yoji Sato, PhD
Head, Division of Drugs
National Institute of Health Sciences, Japan
Currently 4 products are approved for regenerative medicine and other products, moreover, efforts are underway for various research and business development. In this session, we need to understand the outline of the National Consortium established by the Society of Regenerative Medicine, explain the status of support at the academic society and the data registration system and the patient registration system. We discuss the future issues and expectations by asking their opinions from each point of view on issues and expected outcome from databases and ongoing operations.
Speaker(s)
Safety Measures for Regenerative Medical Products in PMS
Kazuhisa Koike, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Office of Medical Devices
Collaboration with Academia for Patient Registration System from Industry Standpoint
Mariko Okada, DVM
JCR Pharmaceutical Co., Ltd., Japan
Director, PV
Outline of Regenerative Medical National Consortium
Kiyoshi Okada, MD, PhD
Osaka University Hospital, Japan
Vice Director, Medical Ctr for Translational Research,Dept of Medical Innovation